Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | BCL2 | P10415 | 4/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083769 | 0.89 | PPARG (0.57) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL17083262 | 0.88 | PPARG (0.56) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL500869 | 0.88 | PPARG (0.56) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL468113 | 0.88 | PPARG (0.56) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL14303544 | 0.88 | PPARG (0.56) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL440723 | 0.87 | PPARA (0.68) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL6674404 | 0.87 | PPARG (0.59) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL3784750 | 0.87 | PPARG (0.59) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL30912525 | 0.87 | PPARG (0.59) | PPARGPPARAACEITGB3ITGA2B | |
| SCHEMBL199415 | 0.87 | PPARA (0.68) | PPARGPPARAACEITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | FREDERIKSEN MATHIAS | 2010-06-10 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| EP-2094645-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008062044-A1 | 2-HYDROXY-1,3-DIAMINOPROPANE DERIVATIVES | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144741-A1 | ETHANOLAMINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | PPARG 4514/4885PPARA 4130/4885ACE 17/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | PPARG 4598/4885PPARA 4050/4885ACE 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.